$KZR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kezar Life Sciences, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kezar Life Sciences, Inc.. Get notifications about new insider transactions in Kezar Life Sciences, Inc. for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 29 2021 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Buy | P | 10.19 | 750 | 7,643 | 11,320 | 10.6 K to 11.3 K (+7.10 %) |
| Jan 11 2021 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Option Exercise | A | 5.45 | 1,200,000 | 6,540,000 | 1,200,000 | |
| Jan 11 2021 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Option Exercise | A | 5.45 | 110,000 | 599,500 | 110,000 | |
| Jan 11 2021 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Option Exercise | A | 5.45 | 220,000 | 1,199,000 | 220,000 | |
| Jan 11 2021 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Option Exercise | A | 5.45 | 260,000 | 1,417,000 | 260,000 | |
| Jan 11 2021 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Option Exercise | A | 5.45 | 260,000 | 1,417,000 | 260,000 | |
| Jan 11 2021 | KZR | Kezar Life Science ... | Henig Noreen | Chief Medical Offic ... | Option Exercise | A | 5.45 | 280,000 | 1,526,000 | 280,000 | |
| Jan 04 2021 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Option Exercise | M | 0.90 | 16,000 | 14,400 | 90,421 | |
| Jan 04 2021 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Buy | M | 0.90 | 16,000 | 14,400 | 359,204 | 343.2 K to 359.2 K (+4.66 %) |
| Jun 26 2020 | KZR | Kezar Life Science ... | COOPER GRAHAM K | Director | Option Exercise | A | 5.60 | 8,896 | 49,818 | 8,896 | |
| Jun 26 2020 | KZR | Kezar Life Science ... | Dinges Jason | Director | Option Exercise | A | 5.60 | 8,896 | 49,818 | 8,896 | |
| Jun 26 2020 | KZR | Kezar Life Science ... | Kauffman Michael | Director | Option Exercise | A | 5.60 | 8,896 | 49,818 | 8,896 | |
| Jun 26 2020 | KZR | Kezar Life Science ... | Sommadossi Jean-Pierre | Director | Option Exercise | A | 5.60 | 8,896 | 49,818 | 8,896 | |
| Jun 26 2020 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Option Exercise | A | 5.60 | 8,896 | 49,818 | 8,896 | |
| Jun 26 2020 | KZR | Kezar Life Science ... | Garner Elizabeth | Director | Option Exercise | A | 5.60 | 8,896 | 49,818 | 8,896 | |
| Jun 15 2020 | KZR | Kezar Life Science ... | Equal Talent Investments Ltd | 10% Owner | Buy | P | 5.50 | 1,454,545 | 7,999,998 | 6,254,545 | 4.8 M to 6.3 M (+30.30 %) |
| Jun 11 2020 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | P | 5.50 | 100,000 | 550,000 | 784,003 | 684 K to 784 K (+14.62 %) |
| May 04 2020 | KZR | Kezar Life Science ... | Henig Noreen | Chief Medical Offic ... | Option Exercise | A | 4.56 | 300,000 | 1,368,000 | 300,000 | |
| Feb 06 2020 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Buy | P | 2.60 | 3,800,000 | 9,880,000 | 6,109,052 | 2.3 M to 6.1 M (+164.57 %) |
| Feb 05 2020 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Buy | P | 2.60 | 38,461 | 99,999 | 38,461 | 0 to 38.5 K |
| Feb 05 2020 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 2.60 | 15,384 | 39,998 | 15,384 | 0 to 15.4 K |
| Feb 05 2020 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Buy | P | 2.60 | 5,769 | 14,999 | 7,570 | 1.8 K to 7.6 K (+320.32 %) |
| Feb 05 2020 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | P | 2.60 | 120,846 | 314,200 | 684,003 | 563.2 K to 684 K (+21.46 %) |
| Feb 05 2020 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Buy | P | 2.60 | 38,461 | 99,999 | 342,609 | 304.1 K to 342.6 K (+12.65 %) |
| Jan 13 2020 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Option Exercise | A | 3.29 | 200,000 | 658,000 | 200,000 | |
| Jan 13 2020 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Option Exercise | A | 3.29 | 90,000 | 296,100 | 90,000 | |
| Jan 13 2020 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Option Exercise | A | 3.29 | 90,000 | 296,100 | 90,000 | |
| Jan 13 2020 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Option Exercise | A | 3.29 | 62,500 | 205,625 | 62,500 | |
| Jan 13 2020 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Option Exercise | A | 3.29 | 62,500 | 205,625 | 62,500 | |
| Jan 13 2020 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Option Exercise | A | 3.29 | 125,000 | 411,250 | 125,000 | |
| Jan 13 2020 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Option Exercise | A | 3.29 | 125,000 | 411,250 | 125,000 | |
| Dec 20 2019 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Option Exercise | M | 0.90 | 50,000 | 45,000 | 106,421 | |
| Dec 20 2019 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Buy | M | 0.90 | 50,000 | 45,000 | 346,954 | 297 K to 347 K (+16.84 %) |
| Dec 19 2019 | KZR | Kezar Life Science ... | Garner Elizabeth | Director | Option Exercise | A | 3.03 | 17,793 | 53,913 | 17,793 | |
| Nov 13 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 2.76 | 800 | 2,207 | 2,000 | 1.2 K to 2 K (+66.67 %) |
| Nov 13 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 2.76 | 800 | 2,207 | 2,000 | 1.2 K to 2 K (+66.67 %) |
| Oct 11 2019 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Buy | P | 3.24 | 1,000 | 3,235 | 296,954 | 296 K to 297 K (+0.34 %) |
| Sep 10 2019 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Option Exercise | A | 3.38 | 35,000 | 118,300 | 35,000 | |
| Sep 10 2019 | KZR | Kezar Life Science ... | Belsky Marc | Chief Financial Off ... | Option Exercise | A | 3.38 | 60,000 | 202,800 | 60,000 | |
| Aug 15 2019 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Buy | P | 4.61 | 5,000 | 23,040 | 302,934 | 297.9 K to 302.9 K (+1.68 %) |
| Aug 14 2019 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Buy | P | 4.66 | 2,000 | 9,310 | 295,954 | 294 K to 296 K (+0.68 %) |
| Aug 12 2019 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Buy | P | 4.97 | 5,000 | 24,830 | 297,934 | 292.9 K to 297.9 K (+1.71 %) |
| Aug 12 2019 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Buy | P | 5.01 | 750 | 3,761 | 293,954 | 293.2 K to 294 K (+0.26 %) |
| Aug 12 2019 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Buy | P | 5.26 | 500 | 2,628 | 293,204 | 292.7 K to 293.2 K (+0.17 %) |
| Aug 12 2019 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Buy | P | 4.96 | 1,020 | 5,057 | 1,451 | 431 to 1.5 K (+236.66 %) |
| Aug 12 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 4.82 | 500 | 2,410 | 1,000 | 500 to 1,000 (+100.00 %) |
| Jul 26 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 5.80 | 56 | 325 | 500 | 444 to 500 (+12.61 %) |
| Jul 26 2019 | KZR | Kezar Life Science ... | Belsky Marc | CFO | Buy | P | 5.65 | 444 | 2,510 | 444 | 0 to 444 |
| Jul 23 2019 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Buy | P | 5.82 | 431 | 2,509 | 431 | 0 to 431 |
| Jun 27 2019 | KZR | Kezar Life Science ... | Sommadossi Jean-Pierre | Director | Option Exercise | A | 7.63 | 8,896 | 67,876 | 8,896 | |
| Jun 27 2019 | KZR | Kezar Life Science ... | Kauffman Michael | Director | Option Exercise | A | 7.63 | 8,896 | 67,876 | 8,896 | |
| Jun 27 2019 | KZR | Kezar Life Science ... | Dinges Jason | Director | Option Exercise | A | 7.63 | 8,896 | 67,876 | 8,896 | |
| Jun 27 2019 | KZR | Kezar Life Science ... | COOPER GRAHAM K | Director | Option Exercise | A | 7.63 | 8,896 | 67,876 | 8,896 | |
| Jun 27 2019 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Option Exercise | A | 7.63 | 8,896 | 67,876 | 8,896 | |
| Mar 06 2019 | KZR | Kezar Life Science ... | Economides Vassiliki | SVP, Strategy & Ext ... | Option Exercise | A | 20.25 | 70,000 | 1,417,500 | 70,000 | |
| Jan 08 2019 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Option Exercise | A | 22.85 | 87,500 | 1,999,375 | 87,500 | |
| Jan 08 2019 | KZR | Kezar Life Science ... | Goel Niti | Chief Medical Offic ... | Option Exercise | A | 22.85 | 75,000 | 1,713,750 | 75,000 | |
| Jan 08 2019 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Option Exercise | A | 22.85 | 175,000 | 3,998,750 | 175,000 | |
| Jan 08 2019 | KZR | Kezar Life Science ... | Belsky Marc | Chief Financial Off ... | Option Exercise | A | 22.85 | 60,000 | 1,371,000 | 60,000 | |
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Option Exercise | C | 0.00 | 125,927 | 0 | 0 | ||
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Option Exercise | C | 0.00 | 210,326 | 0 | 0 | ||
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Option Exercise | C | 0.00 | 125,927 | 0 | 0 | ||
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Buy | C | 0.00 | 125,927 | 0 | 125,927 | 0 to 125.9 K | |
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Option Exercise | C | 0.00 | 210,326 | 0 | 0 | ||
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Buy | C | 0.00 | 210,326 | 0 | 210,326 | 0 to 210.3 K | |
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Buy | C | 0.00 | 125,927 | 0 | 125,927 | 0 to 125.9 K | |
| Jul 05 2018 | KZR | Kezar Life Science ... | STEYER THOMAS F | Buy | C | 0.00 | 210,326 | 0 | 210,326 | 0 to 210.3 K | |
| Jun 28 2018 | KZR | Kezar Life Science ... | BAY CITY CAPITAL LLC | 10% Owner | Option Exercise | C | 0.00 | 472,229 | 0 | 0 | |
| Jun 28 2018 | KZR | Kezar Life Science ... | BAY CITY CAPITAL LLC | 10% Owner | Buy | P | 15.00 | 150,000 | 2,250,000 | 622,229 | 472.2 K to 622.2 K (+31.76 %) |
| Jun 28 2018 | KZR | Kezar Life Science ... | BAY CITY CAPITAL LLC | 10% Owner | Buy | C | 0.00 | 472,229 | 0 | 472,229 | 0 to 472.2 K |
| Jun 27 2018 | KZR | Kezar Life Science ... | Cormorant Asset Management, LP | 10% Owner | Option Exercise | C | 0.00 | 1,007,421 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Cormorant Asset Management, LP | 10% Owner | Option Exercise | C | 0.00 | 315,488 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Cormorant Asset Management, LP | 10% Owner | Buy | P | 15.00 | 250,000 | 3,750,000 | 1,572,909 | 1.3 M to 1.6 M (+18.90 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Cormorant Asset Management, LP | 10% Owner | Buy | C | 0.00 | 1,007,421 | 0 | 1,322,909 | 315.5 K to 1.3 M (+319.32 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Cormorant Asset Management, LP | 10% Owner | Buy | C | 0.00 | 315,488 | 0 | 315,488 | 0 to 315.5 K |
| Jun 27 2018 | KZR | Kezar Life Science ... | Sommadossi Jean-Pierre | Director | Option Exercise | C | 0.00 | 35,258 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Sommadossi Jean-Pierre | Director | Option Exercise | C | 0.00 | 52,581 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Sommadossi Jean-Pierre | Director | Buy | C | 0.00 | 35,258 | 0 | 178,440 | 143.2 K to 178.4 K (+24.62 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Sommadossi Jean-Pierre | Director | Buy | C | 0.00 | 52,581 | 0 | 143,182 | 90.6 K to 143.2 K (+58.04 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Option Exercise | C | 0.00 | 1,007,422 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Option Exercise | C | 0.00 | 1,051,630 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Buy | P | 15.00 | 250,000 | 3,750,000 | 2,309,052 | 2.1 M to 2.3 M (+12.14 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Buy | C | 0.00 | 1,007,422 | 0 | 2,059,052 | 1.1 M to 2.1 M (+95.80 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Buy | C | 0.00 | 1,051,630 | 0 | 1,051,630 | 0 to 1.1 M |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Option Exercise | C | 0.00 | 1,007,422 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Option Exercise | C | 0.00 | 1,051,630 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Buy | P | 15.00 | 250,000 | 3,750,000 | 2,309,052 | 2.1 M to 2.3 M (+12.14 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Buy | C | 0.00 | 1,007,422 | 0 | 2,059,052 | 1.1 M to 2.1 M (+95.80 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Morningside Venture Investment ... | 10% Owner | Buy | C | 0.00 | 1,051,630 | 0 | 1,051,630 | 0 to 1.1 M |
| Jun 27 2018 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Option Exercise | A | 5.91 | 26,690 | 157,738 | 26,690 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Kauffman Michael | Director | Option Exercise | C | 0.00 | 10,516 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Kauffman Michael | Director | Buy | C | 0.00 | 10,516 | 0 | 63,690 | 53.2 K to 63.7 K (+19.78 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Option Exercise | A | 5.91 | 88,967 | 525,795 | 88,967 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Option Exercise | C | 0.00 | 197,076 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Kirk Christopher J. | President and CSO | Option Exercise | A | 5.91 | 26,690 | 157,738 | 26,690 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Option Exercise | C | 0.00 | 262,907 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | P | 15.00 | 50,000 | 750,000 | 563,157 | 513.2 K to 563.2 K (+9.74 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | C | 0.00 | 197,076 | 0 | 513,157 | 316.1 K to 513.2 K (+62.35 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | C | 0.00 | 262,907 | 0 | 316,081 | 53.2 K to 316.1 K (+494.43 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Kauffman Michael | Director | Option Exercise | C | 0.00 | 10,516 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Kauffman Michael | Director | Buy | C | 0.00 | 10,516 | 0 | 63,690 | 53.2 K to 63.7 K (+19.78 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Fowler John Franklin | CEO | Option Exercise | A | 5.91 | 88,967 | 525,795 | 88,967 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Option Exercise | C | 0.00 | 197,076 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Option Exercise | C | 0.00 | 262,907 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Option Exercise | C | 0.00 | 31,481 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | P | 15.00 | 50,000 | 750,000 | 563,157 | 513.2 K to 563.2 K (+9.74 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Option Exercise | C | 0.00 | 105,162 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | C | 0.00 | 197,076 | 0 | 513,157 | 316.1 K to 513.2 K (+62.35 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Buy | C | 0.00 | 31,481 | 0 | 136,643 | 105.2 K to 136.6 K (+29.94 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | BERGER FRANKLIN M | Director | Buy | C | 0.00 | 262,907 | 0 | 316,081 | 53.2 K to 316.1 K (+494.43 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Buy | C | 0.00 | 105,162 | 0 | 105,162 | 0 to 105.2 K |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Option Exercise | C | 0.00 | 31,481 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Option Exercise | C | 0.00 | 105,162 | 0 | 0 | |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Buy | C | 0.00 | 31,481 | 0 | 136,643 | 105.2 K to 136.6 K (+29.94 %) |
| Jun 27 2018 | KZR | Kezar Life Science ... | Aberdare Management Company, L ... | 10% Owner | Buy | C | 0.00 | 105,162 | 0 | 105,162 | 0 to 105.2 K |
| Jun 26 2018 | KZR | Kezar Life Science ... | Chiesi Ventures, Inc. | 10% Owner | Option Exercise | C | 0.00 | 314,819 | 0 | 0 | |
| Jun 26 2018 | KZR | Kezar Life Science ... | Chiesi Ventures, Inc. | 10% Owner | Buy | C | 0.00 | 314,819 | 0 | 314,819 | 0 to 314.8 K |
| Jun 26 2018 | KZR | Kezar Life Science ... | PAPPAS ARTHUR M | 10% Owner | Option Exercise | C | 0.00 | 23,894 | 0 | 0 | |
| Jun 26 2018 | KZR | Kezar Life Science ... | PAPPAS ARTHUR M | 10% Owner | Option Exercise | C | 0.00 | 290,924 | 0 | 0 | |
| Jun 26 2018 | KZR | Kezar Life Science ... | PAPPAS ARTHUR M | 10% Owner | Buy | C | 0.00 | 23,894 | 0 | 23,894 | 0 to 23.9 K |
| Jun 26 2018 | KZR | Kezar Life Science ... | PAPPAS ARTHUR M | 10% Owner | Buy | C | 0.00 | 290,924 | 0 | 290,924 | 0 to 290.9 K |
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Option Exercise | C | 0.00 | 377,783 | 0 | 0 | ||
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Option Exercise | C | 0.00 | 377,783 | 0 | 0 | ||
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Option Exercise | C | 0.00 | 315,489 | 0 | 0 | ||
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Option Exercise | C | 0.00 | 315,489 | 0 | 0 | ||
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Buy | C | 0.00 | 377,783 | 0 | 693,272 | 315.5 K to 693.3 K (+119.75 %) | |
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Buy | C | 0.00 | 377,783 | 0 | 693,272 | 315.5 K to 693.3 K (+119.75 %) | |
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Buy | C | 0.00 | 315,489 | 0 | 315,489 | 0 to 315.5 K | |
| Jun 25 2018 | KZR | Kezar Life Science ... | Omega Fund IV, L.P. | Buy | C | 0.00 | 315,489 | 0 | 315,489 | 0 to 315.5 K | |
| Jun 25 2018 | KZR | Kezar Life Science ... | Onyx Therapeutics, Inc. | 10% Owner | Option Exercise | C | 0.00 | 1,121,384 | 0 | 0 | |
| Jun 25 2018 | KZR | Kezar Life Science ... | Onyx Therapeutics, Inc. | 10% Owner | Buy | C | 0.00 | 1,121,384 | 0 | 1,121,384 | 0 to 1.1 M |
Page: 1